- Home
- ANVS vs CSBR Comparison
ANVS vs CSBR Comparison
Compare ANVS & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | CSBR |
|---|---|---|
| Founded | 2008 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 91.0M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ANVS | CSBR |
|---|---|---|
| Price | $2.69 | $5.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $13.50 | $12.00 |
| AVG Volume (30 Days) | ★ 354.2K | 5.6K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 62.92 | ★ 161.11 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $5.59 |
| 52 Week High | $5.50 | $11.06 |
Technical Indicators
Market Signals| Indicator | ANVS | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 40.76 |
| Support Level | $2.27 | $5.59 |
| Resistance Level | $2.97 | $6.96 |
| Average True Range (ATR) | 0.20 | 0.26 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 55.50 | 14.76 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.